Background. Multiple human papillomavirus (HPV) genotypes may be independently or synergistically associated with risk of high-grade squamous intraepithelial lesions (HSILs). We evaluated the risk of HSIL in women concomitantly infected with multiple HPV genotypes.
Studying the risk of cancer precursors related to individual carcinogenic genotypes is complicated by the high prevalence of infection with multiple carcinogenic genotypes, especially among young women at the peak of sexual transmission of HPV [7, 9] . Biologically, there is no evidence for interaction between HPV genotypes with regard to the risk of cancer; therefore, it can be hypothesized that each infection is independently associated with a risk of precancer and cancer. However, there are controversial reports from cohort studies, some of them suggesting that HPV genotypes in infections involving multiple types act synergistically [10, 11] . Studying HPV genotype interactions is important to understand the biology of HPV infection and progression and to estimate the effect of vaccination on cervical disease outcomes.
Previous studies had limited numbers of disease end points. Here, we evaluated the associations between infection with single and multiple carcinogenic HPV genotypes and the risk of high-grade cytologic lesions in a large population-based study of >59 000 cervical cytology specimens.
METHODS

Population
The study sample was drawn from all 378 992 cervical cytology specimens collected between December 2007 and April 2009 from women residing in New Mexico and ascertained as previously described [12] . HPV genotyping was performed on a sample of 59 664 liquid-based cytology specimens from 7 instate laboratories. A stratified random sample that used 4 strata based on age (≤30 vs >30 years) and cytology result (negative vs atypical squamous cells of undetermined significance [ASC-US] and worse) was used. Because the focus was the influence of HPV vaccination, there was oversampling of younger, cytology-negative women and women of all ages with abnormal cytology findings. Specimens were from 28 355 of 116 488 women (24.3%) aged ≤30 years with negative cytology results, 11 231 of 229 549 (4.9%) aged >30 years with negative cytology results, 11 155 of 18 962 (58.8%) aged ≤30 years with abnormal cytology results, and 8923 of 13 993 (63.8%) aged >30 years with abnormal cytology results (Table 1) were genotyped.
The research reported here was interfaced to the New Mexico HPV Pap Registry (NMHPVPR) and was approved by the University of New Mexico Human Research Review Committee. The NMHPVPR was established to monitor the continuum of cervical screening preventive care and to characterize the population-level influence of HPV vaccination through surveillance and approved research investigations.
HPV Genotyping
The LINEAR ARRAY HPV Genotyping Test (HPV LA; Roche Diagnostics, Indianapolis, IN) is a nonquantitative test for 37 HPV genotypes that incorporates selective polymerase chain of purified DNA was transferred to a tube with 50 µL of HPV Linear Array master mix, and the mixture was amplified by PCR, using the Applied Biosystems (Foster City, CA) gold-plated 96-well GeneAmp PCR System 9700 as specified by the manufacturer. Controls for contamination and assay sensitivity were included in each 96-well assay. By use of the Roche HPV LA detection kit, hybridizations were automated using Tecan ProfiBlot-48 robots (Tecan, Grödig, Austria). The Roche HPV LA Genotyping Test detects 13 highrisk and 24 low-risk HPV types. HPV-52 is not determined directly by a type-specific probe but rather by a probe that crosshybridizes with HPV-33, -35, -52, and -58. The presence of HPV-52 was inferred only if the cross-reactive probe was hybridized but no hybridization was detected for the probes specific for HPV-33, -35, and -58. Notably, concurrent infections involving HPV-52 and any of the 3 other types cannot be detected. Two independent readers interpreted the presence of HPV genotypes, using a reference template provided by the manufacturer. Any discrepancies were identified by a custom computer application applied to the data input and were adjudicated by a third review. The present analysis was restricted to the following 13 carcinogenic types: HPV-16, -18, -31, -33, -35, -39, -45, -51, -52, -56, -58, -59, and -68.
Cervical Cytology
Liquid-based cytology was performed in 7 laboratories, using either ThinPrep (Hologic) or SurePath (BD) liquid-based cytology systems. Cytology results were classified according to the 2001 Bethesda System (TBS): high-grade squamous intraepithelial lesion (HSIL), atypical squamous cells cannot rule out HSIL (ASC-H), atypical glandular cells (AGC), low-grade squamous intraepithelial lesion (LSIL), atypical squamous cells of undetermined significance (ASC-US), and negative for intraepithelial lesion or malignancy. Cytology results reported as cervical intraepithelial neoplasia (CIN) grade 1 were classified as LSIL, and results reported as CIN grade 2 (CIN2), CIN grade 3 (CIN3), carcinoma in situ (CIS), or possible carcinoma were classified as HSIL. Cytology results were based on local readings, and no attempt was made to review them centrally or undertake quality assurance activities.
Statistical Analysis
We calculated proportions of cytology results given the presence of specific genotypes after weighting back to the whole population by using the sampling fractions shown in Table 1 . We stratified the analyses by age (≤30 and >30 years), by infection with single or multiple types, and in infections with multiple types, by whether HPV-16 was present or not. We performed χ 2 tests to evaluate whether the risk of any cytologic abnormality and of HSIL differed across all carcinogenic genotypes present in single infections. Next, for each individual genotype, we performed chi-square tests, comparing the proportion of ASC-US or greater and of HSIL by presence of single or multiple infections, and in multiple infections, whether HPV16 was present or not. We evaluated the influence of the number of carcinogenic types on the risk of cytologic abnormalities by analyzing proportions of cytology categories related to the number of carcinogenic HPV types in the complete sample and after excluding women with HPV-16 infections. Raw P values are presented in the text and tables, with footnotes indicating P values that were statistically significant after conservative Bonferroni correction (P < .0038). This presentation permits an assessment of the results without adjustment for multiple comparisons and with the most conservative correction for multiple comparisons. We ran logistic regression models for the risk of HSIL versus the risk of other cytologic findings, stratified by the number of HPV genotypes detected, and we repeated the runs after excluding women infected with HPV-16. We ran weighted χ 2 tests to examine the role of multiple HPV genotypes, with or without HPV-16, on the risk of HSIL. First, in a model that included all women with at least 1 HPV type, we computed a P value from a χ 2 test for the difference in HSIL between women with 1 versus >1 type. Next, we limited the analysis to women who had multiple (ie, ≥2) types and repeated the analysis to see whether there was any difference between women who had 2 types and those who had ≥3 types. Furthermore, we also compared 2-3 types with ≥4 types. All analyses were run in SAS, version 9.1.
RESULTS
Risk of Abnormal Cytology Results, by HPV Genotype
As the first fundamental observation, for all HPV types, most associated cytology results were negative (Table 2) . Thus, most infections were not accompanied by even equivocal cytologic abnormalities (ASC-US), as diagnosed in routine clinical practice. HPV-16 was the most common carcinogenic HPV genotype in the stratified sample (n = 4234), followed by HPV-51 (n = 2878), HPV-39 (n = 2498), HPV-59 (n = 2275), and HPV-31 (n = 2122; Table 2 ). The least common carcinogenic types in the sample were HPV-45 (n = 1130), HPV-35 (n = 1024), HPV-68 (n = 815), and HPV-33 (n = 591).
For each type (whether occurring alone or with other genotypes), we calculated the proportions of associated cytology results. The highest (weighted) proportions associated with HSIL were observed for HPV-16 (0.036), followed by HPV-33 (0.028), HPV-58 (0.024), HPV-18 (0.022), HPV-35 (0.021), and HPV-31 (0.020; Table 2 ). Importantly, these are not the fractions of HSIL cases associated with each type but, rather, the fractions of the infections associated with HSIL. HPV-56 and HPV-51 had the highest proportions of LSIL (0.209 and 0.159, respectively). We stratified the population by age, using ≤30 years and >30 years, and again evaluated the proportions of cytology results related to individual genotypes (Table 2) . For all genotypes, among women aged >30 years, we observed a higher proportion of negative cytology results and a much lower proportion of LSIL cytology results, compared with the younger group. In contrast, the difference in HSIL risk between the 2 age categories was less consistent: some genotypes (eg, HPV-33 and HPV-51) were associated with a higher risk of HSIL in the younger group, whereas others (eg, HPV-18 and HPV-45) had a higher risk in the older group.
We examined the relationship of HPV type to cytologic abnormality in women infected with a single HPV genotype. Overall, the cytology result (ie, any abnormality vs a negative finding, or HSIL vs a finding less severe than HSIL) differed significantly by HPV genotype (P < .001), based on the distribution of cytology findings in the first row for each genotype in Table 3 . The same heterogeneity was observed when this relationship was analyzed individually in the younger and older age groups (P < .001; Supplementary Tables 1 and 2 ). 
Effect of Coinfections on the Risk of Abnormal Cytology Results for Individual Genotypes
For HPV-16, the risk of HSIL was slightly but not significantly higher in women infected with HPV-16 only, compared with women infected with HPV-16 and ≥1 other carcinogenic type.
For all other types, we observed a greater risk of HSIL in women infected with multiple carcinogenic HPV types that was significant for HPV-31 (P = .003, significant at the Bonferroni threshold), HPV-33 (P = .03), HPV-39 (P = .0004, significant at the Bonferroni threshold), HPV-45 (P = .01), HPV-51 (P = .008), HPV-52 (P = .0001, significant at the Bonferroni threshold), HPV-56 (P = .03), HPV-59 (P < .0001, significant at the Bonferroni threshold), and HPV-68 (P < .002, significant at the Bonferroni threshold; Table 3 ). When comparing infections with multiple types that included HPV-16 with those that did not, all infections with multiple types were shifted to higher cytology categories when they included HPV-16, compared with the multiple-type infections without HPV-16 (for HPV-33, P = .03; for HPV-39, P < .0001, significant at the Bonferroni threshold; for HPV-45, P = .04; for HPV-52, P < .0001, significant at the Bonferroni threshold; for HPV-58, P = .005; and for HPV-59, P < .0001, significant at the Bonferroni threshold), but for all types, the risk of HSIL for infection with multiple types other than HPV-16 was still higher than that for infection with a single type. For all genotypes, we observed a higher risk of LSIL when the genotype was present with other genotypes, compared with when it occurred alone. Notably, for all types except HPV-18 and HPV-35 that were present in women infected with multiple types, the risk of LSIL was higher in women in whom infection included HPV-16 (Table 3) . For each HPV type, in women ≤30 years old coinfection with another type was more common than monoinfection (Supplementary Table 1 ), whereas in women >30 years old monoinfection was more common than coinfection with another type (Supplementary Table 2 ). The risk of LSIL was much lower for all genotypes among older women, compared with that for younger women.
For HPV-16, the risk of HSIL among women aged ≤30 years infected with HPV-16 alone was nonsignificantly greater than the risk for those infected with HPV-16 and ≥1 other carcinogenic type (P = .14; Supplementary Table 1), whereas the risk among women aged >30 years infected with HPV-16 alone was nonsignificantly less than the risk for those infected with HPV-16 and ≥1 other carcinogenic type (P = .09; Supplementary Table 2 ). For most other types, the effects were similar in agestratified analyses, compared with the combined analysis. Consistently for all types, the risk of HSIL was highest for women in whom infection included HPV-16 and ≥1 other type.
Infection With Multiple Carcinogenic HPV Types and the Risk of Abnormal Cytology Results
We analyzed the relationship between the risk of abnormal cytology results and infection with increasing numbers of carcinogenic genotypes. In women infected with multiple types, we observed an increasing proportion with any cytologic abnormality and with HSIL (Table 4) . Compared with the risk of HSIL among women infected with a single HPV type, the risk of HSIL among women infected with 2 types was 1.5-fold greater (95% confidence interval [CI], 1.2-1.8), the risk among women infected with 3 types was 1.7-fold greater (95% CI, 1.3-2.4), and the risk among women infected with ≥4 types was 1.4-fold greater (95% CI, .83-2.5). Although we observed a significant increase in the risk of HSIL among women infected with ≥2 types, compared with those infected with 1 type (P < .0001), we did not see a significant increase between women infected with ≥3 types and those infected with 2 types or between women infected with ≥4 types and those infected with 2 or 3 types (P > .05). In age-stratified analyses, slightly higher risk ratios were observed for women >30 years of age. To evaluate type multiplicity without the effects of HPV-16 in multiple genotype combinations, we repeated the analysis after excluding all women with HPV-16 infections (Table 5) . While the absolute risk of HSIL was lower in HPV-16-negative women (eg, 0.014 for women with 2 carcinogenic types but without HPV-16 vs 0.021 for women with 2 carcinogenic types including HPV-16), the increase in relative risk for women infected with multiple types was very similar to what was observed when HPV-16 was included in the analysis, with risk ratios of 1.5 (95% CI, 1.1-2.0) in women infected with 2 types, 1.7 (95% CI, 1.0-2.9) in women infected with 3 types, and 1.6 (95% CI, .60-4.5) in women Abbreviations: ASC-H, atypical squamous cells, rule out HSIL; ASC-US, atypical squamous cells of undetermined significance; CI, confidence interval; HSIL, highgrade squamous intraepithelial lesion; LSIL, low-grade squamous intraepithelial lesion; NILM, negative for intraepithelial lesion or malignancy. a The age-specific risk for infection with 1 carcinogenic HPV genotype were the reference values used to calculate the age-specific risk ratios (ORs) for infections with >1 carcinogenic HPV genotype. P < .0001, by χ 2 analysis, for the risk of HSIL in women infected with 1 vs those infected with ≥2 genotypes; P > .05, by χ infected with ≥4 types. Similar to the overall analysis, there was a significant increase in risk among women infected with ≥2 types, compared with those infected with 1 type (P = .0007), but we observed no further increase in risk for additional genotypes.
DISCUSSION
Concomitant infection with multiple carcinogenic HPV types is very common, especially among younger women [7] . The effects of concurrent infection with multiple HPV types on cytologic changes and the risk of precancer and cancer are not well understood. It is widely assumed that each HPV genotype acts independently and, thus, should independently contribute to risk of cytologic changes and precancer. To support this notion, it has been demonstrated that individual histologic cervical lesions are usually caused by a single genotype, even if multiple types are present in the cytology specimen [13, 14] . Under this assumption, we would expect to see that concomitant infection with multiple types yields additive effects on the risk of abnormal cytology findings and cervical precancer. However, some previous studies have suggested that infection with multiple HPV types yields synergistic effects [11] , whereas others have not [10] .
In the largest population-based study of disease outcomes in women with HPV genotyping information reported to date, we evaluated the risk of cytologic abnormalities associated with individual genotypes and the role of infection with multiple carcinogenic HPV types.
We demonstrated that most HPV infections do not present in routine practice with even equivocal cytologic abnormalities, confirming previous reports [15, 16] . For all types and type combinations, ASC-US was the most common cytologic abnormality, followed by LSIL, ASC-H, and HSIL. However, the proportion of cytologic abnormalities strongly varied by HPV type, both overall and when analyses were restricted to infection with single carcinogenic types. HPV-16 was most strongly associated with HSIL, whereas HPV-56 was most strongly associated with LSIL. Our findings confirm that HPV-16 is the most dominant etiological type, showing the highest risk association with HSIL, compared with all other genotypes in single infections, and showing an increasing risk for HSIL in all type combinations, compared with other coinfections. These findings support recent data from tissue-based genotyping, showing that when HPV-16 is present with another carcinogenic type in cytology samples, HPV-16 is usually the causal type in cervical lesions [14] .
In our study, women infected with multiple carcinogenic HPV types had a much higher risk of having any cytologic abnormality. Infection with increasing numbers of HPV genotypes had the strongest effect on the LSIL category, with up to a 3-fold increased risk (LSIL proportion, 0.075 among women Overall, we did not see evidence of a more-than-additive effect of the presence of multiple carcinogenic genotypes on high-grade cytology results. In fact, our estimates for the risk of HSIL related to infection with >2 carcinogenic types did not increase beyond the risk observed for infection with 2 carcinogenic genotypes. As outlined above for HPV-16, the strong increase in LSIL findings among women infected with multiple carcinogenic types could mask and attenuate the increase in the risk of HSIL. Also, we cannot exclude residual confounding by age, since younger age is associated with a higher prevalence of infection with multiple types and a lower prevalence of cervical precancer. Our findings support results of a previous study from the Costa Rica Vaccine Trial that did not find evidence for synergism between types in participants infected with multiple types [10] . Another study from Canada reported increasing risks of HSIL in categories of 1 infecting type, 2-3 infecting types, and 4-6 infecting types, with point estimates of risk higher than what would be expected for an additive effect yielded by infection with multiple carcinogenic genotypes [11] . However, the number of end points in that study was low, and the risk estimates had wide and overlapping CIs. Furthermore, the analysis used women without HPV infection as a reference category, possibly leading to unstable estimates for outcomes (ie, LSIL and HSIL) that are very strongly associated with the presence of HPV.
Our analysis has several strengths. We report the largest sample of cervical cytology specimens with HPV genotyping data and cytology results, which was drawn form a large, wellcharacterized, registry-based population of women with cervical cytology test results in the state of New Mexico [12] . HPV genotyping was performed using the well-characterized HPV LA in a single, highly experienced HPV laboratory. We also note some limitations of our study. Our study is purely crosssectional and does not account for prospective risk of disease at this point. Our end points were only based on cytology results. When HSIL is used as a disease end point, the prevalence of cervical precancer is underestimated, because many CIN3 cases are found in women with ASC-US and LSIL [17] .
In summary, we demonstrate that infection with multiple carcinogenic types is associated with a higher risk of any cytologic abnormality and with a risk of HSIL but that the risk is lower than what would be expected assuming an additive risk of HSIL for women infected with multiple genotypes. Thus, in the largest study to date with HPV genotyping data and disease end points, we support that there is no evidence for synergy between HPV genotypes during concomitant infection with multiple HPV types.
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